Organization
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
11 abstracts
Abstract
Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial.Org: Department of Experimental Oncology, Milano, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Vall d'Hebron University Hospital, Bergonié Institute,
Abstract
Efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring NTRK or ROS1 fusions.Org: Roche Products Ltd., Genentech, Memorial Sloan Kettering Cancer Center, Hopp Children’s Cancer Center Heidelberg (KiTZ), Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,
Abstract
Brigatinib monotherapy in children with R/R ALK+ ALCL, IMT, or other solid tumors: Results from the BrigaPED (ITCC-098) phase 1 study.Org: Princess Máxima Center for Pediatric Oncology, Erasmus MC-Sophia Children’s Hospital, University Medical Center Hamburg-Eppendorf, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Children University Hospital,
Abstract
Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study.Org: University of Pisa, Pisa, Italy, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Charité Universitätsmedizin Berlin, Berlin, Germany, Oncology Unit 1, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy, Department of Medical Oncology, University Campus Biomedico, Roma, Italy, Division of Clinical Pharmacology and Oncology, Department of Health Sciences, School of Psychology, University of Florence, Florence, Italy, University of Pisa, Pisa, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS Padua, Padua, Italy, U.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Livorno, Italy, Hämatologisch Onkologische Praxis Eppendorf (HOPE) and Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, Department of Oncology, Istituto Scientifico San Raffaele IRCSS, Milan, Italy, CdC Poliambulanza, Brescia, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS, Padua, Italy, IRCSS-CRO Aviano, Department of Clinical Oncology, Aviano, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Martin Luther University, Halle, Germany, Azienda Ospedaliera Universitaria Pisana, Università degli Studi di Trento, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,
Abstract
Biology and performance of pre- and post-pembrolizumab (Pembro) vesical imaging–reporting and data system (VI-RADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): Full data analysis from a clinical trials pipeline.Org: Vita-Salute San Raffaele University, IRCCS San Raffaele Milano, Veracyte, Inc., IRCCS Ospedale San Raffaele, Radiology Unit,
Abstract
Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAF V600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment.Org: University of Pisa, Pisa, Italy, Azienda Ospedaliero-Universitaria Pisana, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Veneto Institute of Oncology IOV - IRCCS,
Abstract
Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAF V600E mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT).Org: University of Pisa, Pisa, Italy, Azienda Ospedaliero-Universitaria Pisana, Vall d’Hebron Institute of Oncology (VHIO), Veneto Institute of Oncology IOV–IRCCS, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,
Abstract
Clinical characterization of responders to first line (chemo)immunotherapy in platinum-sensitive recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC).Org: Head and Neck Cancer Medical Oncology 3 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Department of Oncology and Hemato-Oncology (DIPO), University of Milano, European Institute of Oncology, Division of Early Drug Development, Head and Neck Cancer Medical Department,
Abstract
Trabectedin (T) versus adriamycin plus dacarbazine (A-DA) in advanced solitary fibrous tumor (SFT): Results from a phase II randomised clinical study (STRADA).Org: IRCCS Foundation National Cancer Institute, Milan, Italy, Molinette Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Fondazione Policlinico Campus Bio-Medico, Orthopaedic Institute Rizzoli,
Abstract
NALIRIFOX vs FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line treatment of advanced pancreatic cancer: An individual patient data pooled analysis of phase 3 registration trials.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Head and Neck Cancer Medical Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan,
Abstract
Effect of SNPs in TMPRSS2 to severe COVID-19 in patients with prostate cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Molecular Immunology Unit, Department of Experimental Oncology, Programma Prostata,